RGNT

Regentis Biomaterials Ltd

• TipRanks·10/02 16:00

  Regentis Biomaterials Is Addressing the ‘Short-Term Relief, Long-Term Failure’ Problem in Knee Cartilage Repair

• TipRanks·09/29 16:30

  Regentis Biomaterials and the Shift from Symptom Management to Structural Repair in Knee Cartilage Care

• Benzinga·09/21 17:06

  12 Health Care Stocks Moving In Monday's Intraday Session

• TipRanks·09/14 16:30

  Regentis Biomaterials (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

• TipRanks·09/11 13:47

  Regentis Biomaterials Posts First-Half 2026 Results as GelrinC Trial Advances and Manufacturing Capacity Jumps

• Benzinga·09/11 13:16

  Regentis Biomaterials H1 EPS $(0.44) Up From $(1.17) YoY

• TipRanks·09/11 13:05

  Regentis Biomaterials reports 1H EPS (44c) vs. ($1.17) last year

• TipRanks·08/28 16:00

  Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC

• TipRanks·08/17 16:00

  Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

• TipRanks·08/14 15:00

  Regentis Biomaterials (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

• TipRanks·08/03 17:30

  Regentis Biomaterials (NYSE American: RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair

• TipRanks·07/30 17:30

  Regentis Biomaterials (NYSE American: RGNT) Targets $3B Cartilage Repair Market with Cell-Free Gelrin C

• TipRanks·07/29 17:00

  Regentis Biomaterials (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Milestones

• Benzinga·07/28 21:06

  12 Health Care Stocks Moving In Tuesday's After-Market Session

• TipRanks·07/27 18:30

  Regentis Biomaterials (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3B Cartilage Repair Market